Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
EQ 
Equillium Inc (EQ)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
03/11/2025: EQ (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit -15.72% | Avg. Invested days 26 | Today’s Advisory WEAK BUY |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 03/11/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 13.90M USD | Price to earnings Ratio - | 1Y Target Price 1 |
Price to earnings Ratio - | 1Y Target Price 1 | ||
Volume (30-day avg) 1472536 | Beta 1.87 | 52 Weeks Range 0.36 - 2.43 | Updated Date 03/31/2025 |
52 Weeks Range 0.36 - 2.43 | Updated Date 03/31/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.23 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -10.05% | Operating Margin (TTM) -5.58% |
Management Effectiveness
Return on Assets (TTM) -9.44% | Return on Equity (TTM) -19.52% |
Valuation
Trailing PE - | Forward PE 1.53 | Enterprise Value -7827369 | Price to Sales(TTM) 0.3 |
Enterprise Value -7827369 | Price to Sales(TTM) 0.3 | ||
Enterprise Value to Revenue 0.06 | Enterprise Value to EBITDA 0.07 | Shares Outstanding 35430800 | Shares Floating 18003434 |
Shares Outstanding 35430800 | Shares Floating 18003434 | ||
Percent Insiders 36.15 | Percent Institutions 19.42 |
Analyst Ratings
Rating 4 | Target Price 4 | Buy 1 | Strong Buy 1 |
Buy 1 | Strong Buy 1 | ||
Hold 1 | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Equillium Inc
Company Overview
History and Background
Equillium, Inc. is a clinical-stage biotechnology company developing novel therapeutics to treat severe autoimmune and inflammatory diseases. Founded to develop therapies to treat a broad range of immuno-inflammatory diseases. Has had limited success to date with its clinical trials.
Core Business Areas
- Immunoinflammatory Disease Therapies: Focuses on developing novel therapies targeting immunoinflammatory diseases. Currently, it's lead compound is itolizumab.
Leadership and Structure
Bruce Steel is the CEO. The company operates with a board of directors and a management team overseeing research, development, and clinical operations.
Top Products and Market Share
Key Offerings
- Itolizumab: A monoclonal antibody designed to selectively block the CD6 receptor, potentially inhibiting the activity of pathogenic T cells. Currently in clinical development stage, thus there is no market share or revenue. Competitors include existing treatments like corticosteroids and other biologics targeting inflammatory pathways.
Market Dynamics
Industry Overview
The biopharmaceutical industry is competitive, with numerous companies developing therapies for autoimmune and inflammatory diseases. It is characterized by high research and development costs, long development timelines, and stringent regulatory requirements.
Positioning
Equillium is a clinical-stage company striving to establish a niche with its CD6-targeting approach. The company is differentiated by the specific mechanism of action of itolizumab.
Total Addressable Market (TAM)
The total addressable market is significant, considering the broad range of autoimmune and inflammatory diseases. It's dependent on successful clinical trials and regulatory approvals of itolizumab. Equillium is positioned to capture a portion of this TAM, if they can deliver a successful drug.
Upturn SWOT Analysis
Strengths
- Novel CD6-targeting approach
- Experienced management team
- Potential for broad application across multiple autoimmune diseases
Weaknesses
- Limited financial resources
- Dependence on the success of itolizumab
- Lack of approved products
Opportunities
- Positive clinical trial results
- Partnerships with larger pharmaceutical companies
- Expansion into new indications
Threats
- Clinical trial failures
- Competition from established therapies
- Regulatory hurdles
- Funding challenges
Competitors and Market Share
Key Competitors
- ABBV
- JNJ
- BMY
- PFE
Competitive Landscape
Equillium faces competition from established players with approved therapies. Its competitive advantage lies in its unique CD6-targeting mechanism of action, but it needs to demonstrate clinical superiority to gain market share.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: Growth trends dependent on clinical trial progress and regulatory approvals. Given they are clinical stage, it is difficult to assess historical growth. No data available as it requires real time financial data.
Future Projections: Future projections are dependent on clinical trial outcomes and market conditions. No data available as it requires real time financial data.
Recent Initiatives: Focusing on clinical trials for Itolizumab.
Summary
Equillium is a clinical-stage biopharmaceutical company focused on developing novel therapies for autoimmune diseases. Their focus is on Itolizumab and clinical testing. This puts a lot of pressure to perform in clinical trials. They face stiff competition from established pharmaceutical companies, so they have to perform very well.
Similar Companies
- ABBV
- JNJ
- BMY
- PFE
Sources and Disclaimers
Data Sources:
- Company filings
- Company Website
- Analyst reports
- Publicly available information
Disclaimers:
This analysis is based on publicly available information and is for informational purposes only. It should not be considered financial advice. Actual results may vary.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Equillium Inc
Exchange NASDAQ | Headquaters La Jolla, CA, United States | ||
IPO Launch date 2018-10-11 | Co-Founder, President, CEO & Director Mr. Bruce D. Steel C.F.A. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 45 | Website https://www.equilliumbio.com |
Full time employees 45 | Website https://www.equilliumbio.com | ||
Equillium, Inc., a clinical-stage biotechnology company, develops and sells products to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need. The company's lead product candidate is itolizumab (EQ001), a first-in-class monoclonal antibody that targets the immune checkpoint receptor CD6, which is in Phase III clinical trials for the treatment of acute graft-versus-host disease; completed Phase I clinical trial for the treatment of ulcerative colitis; and Phase I clinical trial for the treatment of lupus nephritis. It also develops EQ101 completed phase 1/2 for treatment of cutaneous T cell lymphoma and alopecia areata; and EQ302 to treat gastrointestinal indications. In addition, it serves dermatology, gastroenterology, rheumatology, hematology, transplant science, oncology, and pulmonology area. Equillium, Inc. has a research collaboration agreement with Vivtex Corporation to develop GI-targeted formulations for Bi-specific peptide therapy. The company was formerly known as Attenuate Biopharmaceuticals, Inc. and changed its name to Equillium, Inc. in May 2017. Equillium, Inc. was incorporated in 2017 and is headquartered in La Jolla, California.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.